Filing Flows › Regeneron Pharmaceuticals (REGN) › Q3 2026 › vs Q2 2026
Regeneron Pharmaceuticals (REGN) Q3 2026 vs Q2 2026 (quarter over quarter)
Regeneron Pharmaceuticals's revenue rose $825M (+19%) from $4.3B in Q2 2026 to $5.1B in Q3 2026. Operating margin 40.0% against 30.1% (+9.9 pts).
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 40.0% | 30.1% | +9.9 pts |
| Net margin | 38.1% | 30.2% | +7.9 pts |
| Free cash flow margin | 29.0% | 13.3% | +15.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $5.1B | $4.3B | $825M | +19% |
| Other income, net | $236M | $234M | $1.6M | +0.7% |
| Operating profit | $2.0B | $1.3B | $755M | +58% |
| Costs & expenses | $3.1B | $3.0B | $70.4M | +2% |
| Pre-tax earnings | $2.3B | $1.5B | $756M | +50% |
| Research & development | $1.8B | $1.6B | $163M | +10% |
| SG&A | $678M | $662M | $15.7M | +2% |
| Other operating costs | $595M | $704M | −$108M | -15% |
| Net earnings | $1.9B | $1.3B | $652M | +50% |
| Income tax | $335M | $231M | $104M | +45% |
| Depreciation & amortization | $121M | $124M | −$2.7M | -2% |
| Share-based compensation | $256M | $243M | $12.8M | +5% |
| Working capital & other | $542M | $851M | −$308M | -36% |
| Operating cash flow | $1.8B | $813M | $970M | +119% |
| Free cash flow (OCF − capex) | $1.5B | $573M | $910M | +159% |
| Capital expenditures | $300M | $240M | $60.0M | +25% |
Questions
How much did Regeneron Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Regeneron Pharmaceuticals's revenue rose $825M (+19%) from $4.3B in Q2 2026 to $5.1B in Q3 2026. Operating margin 40.0% against 30.1% (+9.9 pts).